Emily Menendez

GU Oncology Now

The phase 3 VISION trial utilized the prostate-specific membrane antigen (PSMA) radioligand therapy [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) plus protocol-permitted standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC) to determine the combination&rsquo;s efficacy in improving radiographic progression-free survival and overall survival.A new analysis of the VISION trial, <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00158-4/fulltext" target="_blank" rel="noopener">led by Karim Fizazi, MD, PhD, revealed additional outcomes</a> related to health-related quality of life (HRQOL), pain, and symptomatic skeletal events.The VISION trial included 831 patients who were enrolled between June 2018 and October 2019. Eligible patients were 18 years of age or older with progressive PSMA-positive mCRPC and an Eastern Cooperative Oncology Group performance status score of 0 to 2. Patients also must have received at least 1 androgen receptor pathway inhibitor and 1 or 2 taxane-containing regimens.Patients were randomly assigned 2:1 to receive either [177Lu]Lu-PSMA-617 plus standard of care ([177Lu]Lu-PSMA-617 group) or standard of care alone (control group). A total of 581 patients were eligible for the trial and randomly assigned to each group for analysis of HRQOL, pain, and time to first symptomatic skeletal event.The median time to first symptomatic skeletal event or death was 11.5 months (95% CI, 10.3-13.2) in the [177Lu]Lu-PSMA-617 group and 6.8 months (range, 5.2-8.5 months) in the control group (hazard ratio, 0.50; 95% CI, 0.40-0.62). Time to worsening in HRQOL was delayed in the [177Lu]Lu-PSMA-617 group over the control group. Grade 3 or 4 adverse events (AEs) included decreased hemoglobin, lymphocyte concentrations, and platelet counts. Treatment-related AEs leading to death occurred in 5 (1%) patients who received [177Lu]Lu-PSMA-617 plus standard of care and in no patients who received standard of care alone.[177Lu]Lu-PSMA-617 plus standard of care was found to delay time to worsening in HRQOL and time to skeletal events compared with standard of care alone. The use of [177Lu]Lu-PSMA-617 in patients with mCRPC who received prior androgen receptor pathway inhibitor and taxane treatment is promising.

[177Lu]Lu-PSMA-617 Plus Standard of Care Versus Standard of Care Alone for Patients With mCRPC

Radioligand therapy prostate-specific membrane antigen

The VISION trial assigned patients with mCRPC to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.

[177Lu]Lu-PSMA-617 + Standard of Care for Patients With mCRPC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe